Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HCM NASDAQ:IMTX NASDAQ:KYMR NASDAQ:MOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHCMHUTCHMED$17.59+0.4%$15.15$11.51▼$21.50$3.07B0.5291,548 shs25,725 shsIMTXImmatics$6.00-3.4%$5.58$3.30▼$13.09$729.30M0.81683,311 shs187,803 shsKYMRKymera Therapeutics$46.18-0.4%$40.99$19.45▼$53.27$3.01B2.18618,113 shs501,454 shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/AA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHCMHUTCHMED0.00%+9.66%+14.00%+27.83%-8.05%IMTXImmatics0.00%+0.50%+2.56%+40.85%-51.18%KYMRKymera Therapeutics0.00%+3.82%-0.56%+77.82%-1.41%MORMorphoSys0.00%0.00%0.00%0.00%+0.58%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHCMHUTCHMED0.6775 of 5 stars1.03.00.00.00.60.01.9IMTXImmatics3.071 of 5 stars3.64.00.00.03.51.70.0KYMRKymera Therapeutics3.1443 of 5 stars4.51.00.00.03.22.50.0MORMorphoSysN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHCMHUTCHMED 2.00Hold$19.008.02% UpsideIMTXImmatics 3.20Buy$14.67144.44% UpsideKYMRKymera Therapeutics 3.05Buy$59.1128.00% UpsideMORMorphoSys 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest IMTX, KYMR, MOR, and HCM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/15/2025KYMRKymera TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/3/2025KYMRKymera TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$70.006/27/2025KYMRKymera TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$56.00 ➝ $53.006/26/2025KYMRKymera TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$59.006/26/2025KYMRKymera TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$57.00 ➝ $53.006/26/2025KYMRKymera TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.00 ➝ $60.006/25/2025KYMRKymera TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$64.006/3/2025KYMRKymera TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.006/3/2025KYMRKymera TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$57.00 ➝ $64.006/3/2025KYMRKymera TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$38.00 ➝ $60.005/28/2025IMTXImmaticsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.00(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHCMHUTCHMED$630.20M4.87$0.29 per share61.24$4.43 per share3.97IMTXImmatics$144.15M5.06$0.24 per share24.56$5.12 per share1.17KYMRKymera Therapeutics$58.89M51.07N/AN/A$12.90 per share3.58MORMorphoSys$238.28M11.99N/AN/A$0.35 per share54.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHCMHUTCHMED$37.73MN/A0.0012.05N/AN/AN/AN/A8/7/2025 (Estimated)IMTXImmatics$16.47M-$0.17N/AN/AN/A-14.73%-4.52%-3.34%8/12/2025 (Estimated)KYMRKymera Therapeutics-$223.86M-$3.10N/AN/AN/A-409.07%-30.11%-25.65%8/6/2025 (Estimated)MORMorphoSys-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/ALatest IMTX, KYMR, MOR, and HCM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q1 2025IMTXImmatics-$0.38N/AN/AN/A$13.05 millionN/A8/6/2025Q2 2025KYMRKymera Therapeutics-$0.84N/AN/AN/A$17.37 millionN/A5/13/2025Q1 2025IMTXImmatics-$0.39-$0.35+$0.04-$0.35$14.92 million$20.12 million5/9/2025Q1 2025KYMRKymera Therapeutics-$0.92-$0.82+$0.10-$0.82$11.38 million$22.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHCMHUTCHMEDN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/AMORMorphoSysN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHCMHUTCHMED0.082.832.70IMTXImmaticsN/A10.2810.28KYMRKymera TherapeuticsN/A8.498.49MORMorphoSys4.981.381.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHCMHUTCHMED8.82%IMTXImmatics64.41%KYMRKymera TherapeuticsN/AMORMorphoSys18.38%Insider OwnershipCompanyInsider OwnershipHCMHUTCHMED3.60%IMTXImmatics3.30%KYMRKymera Therapeutics16.01%MORMorphoSys0.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHCMHUTCHMED1,811174.42 million168.14 millionNot OptionableIMTXImmatics260121.55 million117.54 millionOptionableKYMRKymera Therapeutics17065.12 million54.69 millionOptionableMORMorphoSys730150.62 million150.55 millionNot OptionableIMTX, KYMR, MOR, and HCM HeadlinesRecent News About These CompaniesMaxion Therapeutics Appoints Dr. Stefan Härtle as Chief Development OfficerJune 17, 2025 | finance.yahoo.comEssential Thrombocythemia Market Set for Significant Growth Across 7MM | DelveInsightMarch 21, 2025 | theglobeandmail.comRoyalty Pharma targets $3B share buyback and projects 4-9% growth in 2025 portfolio receiptsFebruary 12, 2025 | seekingalpha.comVIDEO: Triplet therapy improved PFS in relapsed, refractory follicular lymphomaJanuary 15, 2025 | healio.comHNovartis closing Morphosys facilities, laying off 330 workersJanuary 8, 2025 | bioworld.comBSwiss pharma giant Novartis to close biotech firm MorphosysDecember 20, 2024 | swissinfo.chSNovartis to shut MorphSys sites amid pelabresib delayDecember 20, 2024 | thepharmaletter.comTNovartis Cuts MorphoSys Sites in Boston, Munich, Affecting 330 JobsDecember 19, 2024 | biospace.comBNovartis sheds MorphoSys staff, sites after pelabresib delayDecember 19, 2024 | pharmaphorum.comPNovartis shutters MorphoSys sites, lays off staffDecember 19, 2024 | finance.yahoo.comSome 330 jobs hit as Novartis closes Morphosys, WiWo reportsDecember 19, 2024 | reuters.comNovartis raises mid-term sales guidanceNovember 21, 2024 | seekingalpha.comNovartis: launch of Morphosys drug by could be 2027 or laterNovember 21, 2024 | reuters.comIdiopathic Membranous Nephropathy Market Size is estimated to grow with a significant CAGR during the study period (2020-2034).November 14, 2024 | theglobeandmail.comEagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial OfficerNovember 12, 2024 | manilatimes.netMModerna said to shuffle sales leadership; Vertex records first Casgevy saleNovember 6, 2024 | biopharmadive.comBTango stock plunges 28% amid pipeline updates, Q3 earnings reportNovember 6, 2024 | msn.comRegeneron battles Wall Street uncertainty; Madrigal extends fast launch of MASH drugNovember 1, 2024 | biopharmadive.comBSecarna Announces Appointment of Konstantin Petropoulos as Chief Executive OfficeOctober 31, 2024 | pharmiweb.comPNovartis highlights overall M&A track record following MorphoSys impairmentOctober 29, 2024 | endpts.comENew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesD-Wave Is Rising Again Despite Dilution—What’s the Deal?By Nathan Reiff | July 7, 2025View D-Wave Is Rising Again Despite Dilution—What’s the Deal?More Than a Monetary Metal: Silver's Case for OutperformanceBy Jeffrey Neal Johnson | June 22, 2025View More Than a Monetary Metal: Silver's Case for Outperformance3 Stocks Hitting All-Time Highs With More Room to RunBy Dan Schmidt | June 27, 2025View 3 Stocks Hitting All-Time Highs With More Room to RunDon’t Miss Out: 3 Blue-Chips Set to Pop This Earnings SeasonBy Chris Markoch | July 8, 2025View Don’t Miss Out: 3 Blue-Chips Set to Pop This Earnings SeasonBig Bank Buybacks: Morgan Stanley, Citi, & Wells Fargo LeadBy Gabriel Osorio-Mazilli | July 3, 2025View Big Bank Buybacks: Morgan Stanley, Citi, & Wells Fargo LeadIMTX, KYMR, MOR, and HCM Company DescriptionsHUTCHMED NASDAQ:HCM$17.59 +0.07 (+0.40%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$17.57 -0.02 (-0.14%) As of 07/18/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.Immatics NASDAQ:IMTX$6.00 -0.21 (-3.38%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$5.86 -0.15 (-2.42%) As of 07/18/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Kymera Therapeutics NASDAQ:KYMR$46.18 -0.17 (-0.37%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$46.87 +0.69 (+1.50%) As of 07/18/2025 05:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.MorphoSys NASDAQ:MOR$18.96 0.00 (0.00%) As of 07/18/2025MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
